Hemlibra is a medication used for the prophylactic treatment of patients with Factor VIII hemophilia with or without inhibitors. Hemlibra is a bi-specific antibody (can simultaneously bind to two antigen) that mimics the role of Factor VIII in clotting.
Since Hemlibra is not actual Factor VIII, it works even in patients with inhibitors. Hemlibra is given as a tiny injection under the skin at a frequency of every week, every other week, or every four weeks to prevent bleeding.
This medication is used for prevention only and should not be used to treat an active bleed, and it will only work in FVIII hemophilia and not FIX.
If bleeding events occur, the patient will need to infuse Factor VIII concentrate (or Factor VIIa in the case of inhibitor) to treat the bleed.
Call the IHTC at 317.871.0000 to schedule an appointment to determine whether the use of Hemlibra is right for you or your child.